Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
President Barack Obama’s health care plan would cost Indianapolis-based Eli Lilly and Co. “several hundred million” dollars in U.S. sales, a Lilly spokesman said today.
If enacted, the plan would require drugmakers to give larger rebates to the federal Medicaid program, raising them to 21 percent from 15 percent off the list price.
That proposal would hit Lilly’s bestselling drug Zyprexa, an antipsychotic, which derives a large chunk of its sales from Medicaid patients.
In 2009, Zyprexa recorded U.S. sales of $2.2 billion.
Please enable JavaScript to view this content.